NeuroSense prices $4.5M registered direct offering at $1.50 per share

NeuroSense Therapeutics announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 2,980,000 ordinary shares in a registered direct offering and ordinary warrants to purchase up to 2,980,000 ordinary shares in a concurrent private placement at a combined purchase price of $1.50 per ordinary share. The ordinary warrants issued pursuant to the concurrent private placement will have an exercise price of $1.50 per ordinary share, will be immediately exercisable and will expire 5 years from the initial exercise date. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.